false
0001582554
DE
0001582554
2023-11-07
2023-11-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November
7, 2023
MATINAS
BIOPHARMA HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38022 |
|
46-3011414 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
ID Number) |
1545
Route 206 South,
Suite
302
Bedminster,
New Jersey |
|
07921 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (908)
484-8805
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
Common
Stock |
|
MTNB |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 |
Regulation
FD Disclosure. |
On
November 7, 2023, Matinas BioPharma Holdings, Inc. (the “Company”) announced results from an in vivo animal study
of its oral lipid nanocrystal (“LNC”) formulation of docetaxel. A copy of the press release is furnished as Exhibit 99. 1
hereto and incorporated herein by reference.
The
information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On
November 7, 2023, the Company announced positive results from an in vivo animal study of its oral LNC formulation of docetaxel,
a chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors. Currently, docetaxel is administered
intravenously and can be associated with significant side effects and toxicities. The study demonstrated reductions in tumor size comparable
to systemic intravenous docetaxel in a well-validated mouse melanoma model. No toxicity was observed with the LNC formulations over the
10 days of oral dosing. The course of treatment primarily targeted efficacy and requires further study and evaluation with longer periods
of administration.
Study
Design
Purpose:
Document the efficacy of an oral LNC docetaxel formulation to target and treat tumors, with both negative (untreated) and positive (IV
docetaxel) controls.
| ● | Syngeneic
tumor model (C57BL/6 mice injected with B16F10 murine melanoma cells) |
| ● | Four
treatment groups |
| ○ | Untreated
controls |
| ○ | Low-dose
oral LNC docetaxel |
| ○ | High-dose
oral LNC docetaxel |
| ○ | IV
docetaxel |
| ● | Dosing
of oral LNCs and IV docetaxel initiated at Day 5 following tumor cell injection |
| ● | Low-dose
and high-dose oral LNC arms dosed daily through Day 14 |
| ● | IV
docetaxel administered on Day 5 and Day 10 |
| ● | Tumor
volume (caliper measurements) measured throughout the course of treatment |
| ● | Toxicity
monitored throughout treatment and assessment of hematologic parameters at Day |
| ● | Animal
sacrifice at Day 14 |
| ● | Tumor
volume measured at Day 14 |
Key
Findings
| ● | Efficacy:
Anti-tumor effect of daily oral LNC docetaxel in both the high-dose and low-dose arms were
comparable to intravenous docetaxel with statistically significant reductions in tumor volume
compared with untreated controls at Day 14 (high dose oral LNC -63%; low dose oral LNC -57%;
IV docetaxel -68%), and similar reductions in tumor weight at Day 14. |
| ● | Safety:
No systemic toxicities were noted. Body weight was stable over treatment duration and hematologic
parameters were similar to untreated controls. |
The
Company is considering evaluating the efficacy of the current LNC docetaxel formulation in other tumor models and evaluating longer-term
treatment regimens to confirm lack of toxicity. The Company plans to evaluate the potential anti-tumor activity of LNC formulations of
small oligonucleotides.
Forward-
Looking Statements
This
Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating
to the Company’s strategic focus and the future development of its product candidates, including MAT2203, the anticipated timing
of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s
ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable
terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend
upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking
statements.
These
statements may be identified by the use of forward-looking expressions, including, but not limited to, “expects,” “anticipates,”
“intends,” “plans,” “could,” “believes,” “estimates” and similar expressions.
These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, the Company’s ability to obtain additional capital to meet its liquidity
needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our
product candidates; the ability to successfully complete research and further development and commercialization of our product candidates;
the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect
the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in
the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under
“Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of the date hereof. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. The Company’s product candidates are all in a development
stage and are not available for sale or use.
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MATINAS
BIOPHARMA HOLDINGS, INC. |
|
|
|
Dated:
November 9, 2023 |
By:
|
/s/
Jerome D. Jabbour |
|
|
|
|
Name: |
Jerome D. Jabbour |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
Matinas
BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Study
results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity
BEDMINSTER,
N.J. (November 7, 2023) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical
company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive results
from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management
of multiple metastatic and unresectable tumors. Currently, docetaxel is administered intravenously and can be associated with significant
side effects and toxicities.
“We
are excited to report new in vivo data demonstrating the therapeutic efficacy of an oral LNC formulation of docetaxel,”
said Dr. James J. Ferguson, Chief Medical Officer of Matinas. “We believe this is a step forward for Matinas’ unique
drug delivery platform, taking us beyond our successes in infectious disease by providing convincing proof-of-principle that orally administered
LNCs can effectively target tumors and successfully deliver small molecule therapeutics to those tumors.
“The
study shows reductions in tumor size comparable to systemic intravenous docetaxel in a well-validated mouse melanoma model,” he
added. “We observed no toxicity with our LNC formulations over the 10 days of oral dosing, noting this relatively short course
of treatment was primarily targeting efficacy and will require further study and evaluation with longer periods of administration. Additional
analyses of the data are ongoing, and we are preparing them for presentation at upcoming scientific meetings.”
Study
Design
Purpose:
Document the efficacy of an oral LNC docetaxel formulation to target and treat tumors, with both negative (untreated) and positive (IV
docetaxel) controls.
| ● | Syngeneic
tumor model (C57BL/6 mice injected with B16F10 murine melanoma cells) |
| ● | Four
treatment groups |
| ■ | Untreated
controls |
| ■ | Low-dose
oral LNC docetaxel |
| ■ | High-dose
oral LNC docetaxel |
| ■ | IV
docetaxel |
| ● | Dosing
of oral LNCs and IV docetaxel initiated at Day 5 following tumor cell injection |
| ● | Low-dose
and high-dose oral LNC arms dosed daily through Day 14 |
| ● | IV
docetaxel administered on Day 5 and Day 10 |
| ● | Tumor
volume (caliper measurements) measured throughout the course of treatment |
| ● | Toxicity
monitored throughout treatment and assessment of hematologic parameters at Day 14 |
| ● | Animal
sacrifice at Day 14 |
| ● | Tumor
volume measured at Day 14 |
Key
Findings
| ● | Efficacy:
Anti-tumor effect of daily oral LNC docetaxel in both the high-dose and low-dose arms were
comparable to IV docetaxel with statistically significant reductions in tumor volume compared
with untreated controls at Day 14 (high dose oral LNC -63%; low dose oral LNC -57%; IV docetaxel
-68%), and similar reductions in tumor weight at Day 14. |
| ● | Safety:
No systemic toxicities were noted. Body weight was stable over treatment duration and hematologic
parameters were similar to untreated controls. |
Potential
next steps for Matinas include evaluating the efficacy of the current LNC docetaxel formulation in other tumor models and evaluating
longer-term treatment regimens to confirm lack of toxicity. Additionally, Matinas plans to evaluate the potential anti-tumor activity
of LNC formulations of small oligonucleotides.
About
Matinas BioPharma
Matinas
BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery
technology.
Matinas’
lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent,
can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant
nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital
setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2
EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated
as an oral step-down monotherapy treatment following IV amphotericin B in a single pivotal Phase 3 study in the treatment of aspergillosis
in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance
or for whom these antifungal agents are unable to be used for other clinical reasons.
In
addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to
many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger,
more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action
and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred
next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
Forward-looking
Statements
This
release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to our business activities, our strategy and plans, our collaboration with National Resilience, Inc., the potential
of our LNC platform technology, and the future development of its product candidates, including MAT2203, the Company’s ability
to identify and pursue development, licensing and partnership opportunities for its products, including MAT2203, or platform delivery
technologies on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive
in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements
that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,”
“intends,” “plans,” “could,” “believes,” “estimates” and similar expressions.
These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability to continue as a going concern, our ability to obtain additional
capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete
the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization
of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals;
our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other
factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned
not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required
by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product
candidates are all in a development stage and are not available for sale or use.
Investor
Contact
LHA
Investor Relations
Jody
Cain
Jcain@lhai.com
310-691-7100
#
# #
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Matinas Biopharma (AMEX:MTNB)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Matinas Biopharma (AMEX:MTNB)
Storico
Da Giu 2023 a Giu 2024